教員紹介

SDGsへの取り組み

最終学歴

東京大学大学院薬学系研究科 生命薬学専攻 博士後期課程退学 薬学博士（東京大学）

取得学位

博士（薬学）

所属学会

日本薬物動態学会、日本薬剤学会、日本臨床薬理学会、日本動物実験代替法学会

現在の専門分野

分子薬物動態学、臨床薬理学

現在の研究課題

薬物・内因性化合物の体内動態解析を基にした、ヒトにおける薬効・副作用の個人差を予測するための研究

主要研究業績

●生理学的薬物速度論（PBPK）モデルを用いた薬物間相互作用予測法の構築

●in vitro-in vivo補外法に基づいた生体膜輸送過程の解析

●自主臨床試験データを用いた血中・臓器中薬物濃度の解析および予測

最近の研究業績

1. Sato M, Toshimoto K, Tomaru A, Yoshikado T, Tanaka Y, Hisaka A, Lee W, Sugiyama Y. Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake as A Major Contributor to Its Nonlinear Pharmacokinetics. Drug Metab Dispos. 2018 Feb 23. pii: dmd.117.078972. doi: 10.1124/dmd.117.078972. [Epub ahead of print]

2. Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y. Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin. Drug Metab Dispos. 2018 Feb 12. pii: dmd.117.078816. doi: 10.1124/dmd.117.078816. [Epub ahead of print]

3. Takehara I, Terashima H, Nakayama T, Yoshikado T, Yoshida M, Furihata K, Watanabe N, Maeda K, Ando O, Sugiyama Y, Kusuhara H. Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers. Pharm Res 34:1601-14 (2017)

4. Yoshikado T, Maeda K, Kusuhara H, Furihata K, Sugiyama Y. Quantitative analyses of the influence of parameters governing rate-determining process of hepatic elimination of drugs on the magnitudes of drug-drug interactions via hepatic OATPs and CYP3A using physiologically-based pharmacokinetic models. J Pharm Sci 106:2739-50 (2017)

5. Yoshikado T, Maeda K, Furihata S, Terashima H, Nakayama T, Ishigame K, Tsunemoto K, Kusuhara H, Furihata K, Sugiyama Y. A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions. Pharm Res 34:1570-83 (2017)

6. Kim SJ, Toshimoto K, Yao Y, Yoshikado T, Sugiyama Y. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. J Pharm Sci 106:2715-26 (2017)

7. Yoshikado T, Toshimoto K, Nakada T, Ikejiri K, Kusuhara H, Maeda K, Sugiyama Y. Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins. Drug Metab Dispos 45:779-89 (2017)

8. Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Kanda E, Izumi N, Kusuhara H, Sugiyama Y. Small-dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of Five Probes for OATP2B1 and BCRP. J Pharm Sci 106:2688-94 (2017)

9. Yoshikado T, Yoshida K, Kotani N, Nakada T, Asaumi R, Toshimoto K, Maeda K, Kusuhara H, Sugiyama Y. Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter-optimization method. Clin Pharmacol Ther 100:513-23 (2016)

10. Kim SJ, Yoshikado T, Ieiri I, Maeda K, Kimura M, Irie S, Kusuhara H, Sugiyama Y. Clarification of the mechanism of clopidogrel-mediated drug–drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab Dispos 44:1622-32 (2016)

11. Yoshikado T, Takada T, Yamamoto H, Tan JK, Ito K, Santa T, Suzuki H. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites. Mol Pharmacol 83:552-62 (2013)

12. Ikebuchi Y, Shimizu H, Ito K, Yoshikado T, Yamanashi Y, Takada T, Suzuki H. Ursodeoxycholic acid stimulates the formation of the bile canalicular network. Biochem Pharmacol 84:925-35 (2012)

13. Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, Yokota H, Yatomi Y, Yoshida H, Goto J, Tsuji S, Suzuki H. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 79:241-50 (2011)

14. Yamanashi Y, Takada T, Yoshikado T, Shoda J, Suzuki H. NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Gastroenterology 140:1664-74 (2011)

受賞

第７回マンダム動物実験代替法国際研究助成（マンダム賞）